Telix Pharmaceuticals logo

TLX - Telix Pharmaceuticals Share Price

A$4 -0.1  -1.7%

Last Trade - 1:39am

Mid Cap
Market Cap £639.5m
Enterprise Value £597.0m
Revenue £2.92m
Position in Universe 281st / 1899
Unlock TLX Revenue
Relative Strength (%)
1m -5.12%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -15.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.20 3.49 5.21 35.8 85.1
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, TelixPharmaceuticals Ltd revenues increased 50% to A$5.2M. Netloss increased 61% to A$44.9M. Revenues reflect Licenses ofintellectual property segment increase from A$0K to A$1.4M,Research and development services segment increase fromA$0K to A$533K. Higher net loss reflects Fair valueremeasurement of contingent c increase from A$2.3M toA$7.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for TLX
Graphical History


TLX Revenue Unlock TLX Revenue

Net Income

TLX Net Income Unlock TLX Revenue

Normalised EPS

TLX Normalised EPS Unlock TLX Revenue

PE Ratio Range

TLX PE Ratio Range Unlock TLX Revenue

Dividend Yield Range

TLX Dividend Yield Range Unlock TLX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
TLX EPS Forecasts Unlock TLX Revenue
Profile Summary

Telix Pharmaceuticals Limited is a clinical-stage biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer). The Company, through its subsidiary TheraPharm GmbH, is engaged in the research, development and manufacturing of monoclonal antibodies for targeted radiation of hematopoietic malignant and non-malignant diseases, lymphoproliferative diseases, conditioning for allogeneic stem cells, as well as in diagnostics of inflammatory diseases and bone marrow metastases.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated January 3, 2017
Public Since November 15, 2017
No. of Shareholders: 4,827
No. of Employees: 60
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 280,405,322
Free Float (0.0%)
Eligible for
TLX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for TLX
Upcoming Events for TLX
Frequently Asked Questions for Telix Pharmaceuticals
What is the Telix Pharmaceuticals share price?

As of 1:39am, shares in Telix Pharmaceuticals are trading at A$4, giving the company a market capitalisation of £639.5m. This share price information is delayed by 15 minutes.

How has the Telix Pharmaceuticals share price performed this year?

Shares in Telix Pharmaceuticals are currently trading at A$4 and the price has moved by 0.241k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Telix Pharmaceuticals price has moved by 0.157k% over the past year.

What are the analyst and broker recommendations for Telix Pharmaceuticals?

Of the analysts with advisory recommendations for Telix Pharmaceuticals, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Telix Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Telix Pharmaceuticals next release its financial results?

Telix Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Telix Pharmaceuticals dividend yield?

Telix Pharmaceuticals does not currently pay a dividend.

Does Telix Pharmaceuticals pay a dividend?

Telix Pharmaceuticals does not currently pay a dividend.

When does Telix Pharmaceuticals next pay dividends?

Telix Pharmaceuticals does not currently pay a dividend.

How do I buy Telix Pharmaceuticals shares?

To buy shares in Telix Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Telix Pharmaceuticals?

Shares in Telix Pharmaceuticals are currently trading at A$4, giving the company a market capitalisation of £639.5m.

Where are Telix Pharmaceuticals shares listed? Where are Telix Pharmaceuticals shares listed?

Here are the trading details for Telix Pharmaceuticals:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: TLX
What kind of share is Telix Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Telix Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Telix Pharmaceuticals share price forecast 2021?

Shares in Telix Pharmaceuticals are currently priced at A$4. At that level they are trading at 14.91% discount to the analyst consensus target price of 0.00.

Analysts covering Telix Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -0.097 for the next financial year.

How can I tell whether the Telix Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Telix Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 0.102k%. At the current price of A$4, shares in Telix Pharmaceuticals are trading at 43.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Telix Pharmaceuticals PE Ratio?

We were not able to find PE ratio data for Telix Pharmaceuticals.

Who are the key directors of Telix Pharmaceuticals?

We were unable to find the directors for Telix Pharmaceuticals.

Who are the major shareholders of Telix Pharmaceuticals?

Here are the top five shareholders of Telix Pharmaceuticals based on the size of their shareholding:

FIL Investment Management (Hong Kong) Limited Investment Advisor
Percentage owned: 8.87% (25.0m shares)
Behrenbruch (Christian P. Ph.D.) Individual Investor
Percentage owned: 8.77% (24.7m shares)
Kluge (Andreas) Individual Investor
Percentage owned: 8.77% (24.7m shares)
Grand Decade Developments Ltd. Corporation
Percentage owned: 7.44% (20.9m shares)
Fidelity Funds - Pacific Fund Mutual Fund
Percentage owned: 7.31% (20.6m shares)
Similar to TLX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.